Explore unlimited financial markets on Injective’s fast, secure, and fully decentralized layer-2 DEX Trailblazing the new dawn of Decentralized Finance
Injective Protocol provides traders unparalleled access to new decentralized derivatives markets without any restrictions.
What Is Injective Protocol (INJ)?
The Injective Protocol project is a revolutionary idea that aims to make currency exchanges completely decentralized, public operated networks. What this means is the exchange is solely operated by people who hold INJ tokens. There is no centralized governing body that enforces control over the development of the project. The Injective Protocol project officially launched via a public offering in 2020, and it was backed by names in the industry like Binance, Pantera and Hashed.
The Injective Chain is the blockchain foundation of the project. It hosts a completely decentralized order book and employs elements from the Ethereum Virtual Machine (EVM). The platform also incorporates a bi-directional token bridge, linking it to the Ethereum ecosystem.
Who Are the Founders of Injective Protocol?
Eric Chen is the co-founder of Injective Labs, the company behind INJ. He has a bachelor of science in finance from NYU Stern, and his professional career started back in 2014. Chen was a research fellow at Desay Sv Automotive, and later moved to AXA Advisors to become an analyst. In 2017, Eric Chen became a researcher for Innovating Capital, and a year later, in 2018, he co-founded Injective Protocol.
Albert Chon is the chief technical officer of Injective Protocol. He graduated with a computer science masters degree from Stanford University and became a full stack engineer for Linc Global in 2017. At the beginning of 2018, he started a position at Amazon as a software development engineer; however, he soon moved on to co-found Injective Protocol with Eric Chen. He has been with the company since its launch in mid-2018.
